Akebia Therapeutics Upgraded to Hold by Zacks Research

Analysts cite improved outlook for the biotech company's lead drug candidate.

Apr. 9, 2026 at 10:52am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of various mechanical components and industrial equipment, representing the unseen forces that drive the financial markets.An extreme close-up of the intricate machinery powering the financial industry hints at the complex systems underlying stock market fluctuations and corporate earnings.Cambridge Today

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company focused on kidney disease treatments, was upgraded from a 'strong sell' to a 'hold' rating by analysts at Zacks Research. The upgrade comes as the company's lead drug candidate, vadadustat, shows promise in clinical trials for treating anemia associated with chronic kidney disease.

Why it matters

Akebia Therapeutics has faced challenges in recent years, with its stock price declining significantly. However, the Zacks Research upgrade suggests a more positive outlook for the company's future, potentially signaling improved prospects for its lead drug and the overall business.

The details

In a research note, Zacks Research cited the progress of vadadustat in clinical trials as the primary reason for the rating upgrade. The analysts noted that several other research firms have also issued positive assessments of the drug, with ratings ranging from 'buy' to 'hold'.

  • Zacks Research issued the rating upgrade on Tuesday, April 9, 2026.

The players

Akebia Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for patients with kidney disease, including its lead drug candidate, vadadustat.

Zacks Research

An independent equity research firm that provides analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We are encouraged by the progress of vadadustat and believe the drug has the potential to address a significant unmet need for patients with chronic kidney disease.”

— Zacks Research Analyst

What’s next

Akebia Therapeutics is expected to provide an update on the development of vadadustat during its next quarterly earnings report, scheduled for May 2026.

The takeaway

The Zacks Research upgrade suggests a potential turnaround for Akebia Therapeutics, as the company's lead drug candidate continues to show promise in clinical trials. This could signal improved prospects for the company and its shareholders, though challenges remain in the highly competitive kidney disease treatment market.